Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
POZN > SEC Filings for POZN > Form 8-K on 23-Dec-2013All Recent SEC Filings

Show all filings for POZEN INC /NC

Form 8-K for POZEN INC /NC


23-Dec-2013

Other Events


Item 8.01 Other Events.

Over the past few weeks POZEN Inc. (the "Company") has been corresponding with and providing additional information to the United States Food & Drug Administration (the "FDA") concerning its New Drug Application ("NDA") for PA32540 and PA8140 tablets. In connection with these discussions, the Company has decided to conduct a comparative Phase 1 pharmacokinetic study. The goal of the study is to determine the pharmacokinetic profile of the omeprazole component of PA 8140 tablets and compare to that of PA32540 tablets. Both PA dosage forms contain 40mg of omeprazole in an immediate release form and are manufactured using nearly identical procedures.

The Company anticipates that this study, which will enroll up to 30 subjects, will cost approximately $750,000. Final data are expected to be available in March 2014. The Company and the FDA have agreed that the Company will submit study information and data to the FDA as it becomes available during the conduct of the study and that FDA will review such information and data from the study when submitted. FDA has informed the Company that the Company's user fee date (the "PDUFA Date") is now April 25, 2014.


  Add POZN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for POZN - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.